Recent Updates
Recently added Catalysts
ESLA Positive Sentiment

Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models

Key Takeaway: Estrella Immunopharma announced promising preclinical data for its ARTEMIS T-cell therapy, which demonstrated significant leukemia responses and better extramedullary disease clearance compared to traditional CAR-T therapies. These findings will be presented at the ASH Annual Meeting in December 2026, showcasing the therapy's potential in cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • ARTEMIS T-cell therapy shows deep and durable leukemia responses.
  • Superior clearance of extramedullary disease compared to CAR-T.
  • Findings accepted for presentation at a major conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
EB103
Phase 2 · B-Cell Non-Hodgkin's Lymphoma (NHL)

Full Press Release Details

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell therapies for cancer and autoimmune diseases, today highlighted preclinical findings from an abstract accepted for poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans, Louisiana. The research, described in

Frequently Asked Questions

What is the ARTEMIS T-cell therapy?

ARTEMIS is a next-generation T-cell therapy developed by Estrella Immunopharma.

When will the ARTEMIS data be presented?

The data will be presented at the ASH Annual Meeting from December 12-15, 2026.

How does ARTEMIS compare to CAR-T therapy?

ARTEMIS shows superior extramedullary disease clearance compared to conventional CAR-T.

What were the findings of the preclinical study?

The study demonstrated deep and durable responses in leukemia treatment.

Last updated: Nov 16, 2026